Prostate Cancer Survivors

 

YANA - YOU ARE NOT ALONE NOW

PROSTATE CANCER SUPPORT SITE

 

 

This forum is for the discussion of anything to do with Prostate Cancer.
There are only four rules:

  • No fundraisers, no commercials (although it is OK to recommend choices of treatment or medical people based on your personal research; invitations to participate in third-party surveys are also acceptable, provided there is no compensation to YANA);
  • No harvesting e-mail addresses for Spam;
  • No insults or flaming - be polite and respectful at all times and understand that there may be a variety of points of view, all of which may have some validity;
  • Opinions are OK, but please provide as much factual evidence as possible for any assertions that you are making

Failure to abide by these simple rules will result in the immediate and permanent suspension of your posting privileges.

Since this is an International Forum, please specify your location in your post.

General Forum
Start a New Topic 
Author
Comment
View Entire Thread
Re: Genomic Health - Oncotype DX® Genomic Prostate Score (GPS

Mike Scott seems to be on top of Myraid Polaris - Prolaris: prognostically accurate but of limited utility?

In part he says:

In theory, these data suggest that the Prolaris test should be capable of discriminating between good and poor candidates for active surveillance. However, there may be a fly in the ointment. As yet we are not aware of any data showing that the Prolaris test can make accurate predictions based on tissue from an initial prostate biopsy, but such biopsy-derived tissue is what is available to the pathologist in the vast majority of cases prior to a decision whether to treat or to monitor individual patients. If the Prolaris test can only be used with accuracy on tissue available after a TURP or a radical prostatectomy, this will severely curtail the potential utility of this test.

I assume you aren't going to have surgery to get enough material for the test?

RETURN TO HOME PAGE LINKS